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Purpose: To investigate intraplaque hemorrhage (IPH) development 
and change over time.
Materials and 
Methods:
Institutional review board approval and written informed 
consent from all participants were obtained. From a pop-
ulation-based study on subclinical atherosclerosis, 40 par-
ticipants with IPH at baseline magnetic resonance (MR) 
imaging (53 carotids with IPH) were randomly selected 
and were matched with 27 control subjects (53 carotids 
without IPH) to undergo a second MR examination (mean 
interval, 17 months 6 4 [standard deviation]) to assess 
IPH change. IPH volume change was evaluated by using 
both a visual rating scale and an automated volumetric 
segmentation tool. Cardiovascular risk factors for IPH 
volume change were investigated with linear regression 
analyses.
Results: IPH remained present in 50 (94%) of the 53 carotids with 
IPH at baseline, and it developed in five (7%) of the 40 ca-
rotids without IPH at baseline. Visual progression of IPH 
volume was present in 14 (26%) of the 53 carotids with 
IPH at baseline, and regression was present in 16 (30%). 
Mean quantitative change in IPH volume was 213.7 mm3 
6 62.6 per year of follow-up. Male sex (men vs women, 
37.7 mm3; 95% confidence interval [CI]: 11.0, 64.4; P = 
.006), smoking (smokers vs nonsmokers, 45.2 mm3; 95% 
CI: 7.1, 83.4; P = .020), and hypertension (subjects with 
hypertension vs those without hypertension, 32.5 mm3; 
95% CI: 7.7, 57.2; P = .010) were associated with IPH 
volume change.
Conclusion: During 17 months of follow-up, both visual progression 
and regression of IPH volume occurs, whereas quantita-
tively IPH volume decreases. This suggests that IPH is a 
dynamic process with potential for either growth or res-
olution over time.
q RSNA, 2016
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underwent a complete MR imaging ex-
amination and image review according 
to previously described protocols (12). 
In 113 of these 360 participants, there 
was uni- or bilateral carotid IPH. For 
this case-control study, we randomly in-
vited 40 subjects with IPH and selected 
30 age-, sex-, and plaque thickness–
matched subjects without IPH (n = 30) 
to undergo serial MR imaging after ap-
proximately 1.5 years. Subjects with 
prior carotid endarterectomy were not 
invited. Three invited control subjects 
refused to participate. All 40 invited 
subjects and the remaining 27 control 
subjects underwent serial imaging (67 
participants in total). The mean interval 
between examinations was 17 months 
6 4 (standard deviation) (range, 11–24 
months). The Rotterdam study has 
been approved by the institutional re-
view board of Erasmus Medical Center 
(Rotterdam, the Netherlands) accord-
ing to the Population Study Act Rotter-
dam Study, executed by the Ministry of 
Health, Welfare and Sports of the Neth-
erlands. Written informed consent was 
obtained from all participants.
MR Image Acquisition and Review
All MR images were obtained with the 
same 1.5-T unit (GE Signa Excite II; GE 
Healthcare, Milwaukee, Wis) at both 
time points with a bilateral phased-
array surface coil. The MR imaging 
protocol has been described in detail 
carotid atherosclerosis score that asso-
ciates with IPH presence has been de-
scribed (8); however, in a longitudinal 
study, this score could not be used to 
predict development of new IPH (9). In 
all these previous studies, researchers 
considered IPH as only a dichotomous 
variable and did not study change in 
IPH volume over time. One report used 
IPH area size to predict cerebrovascu-
lar risk; however, MR imaging was per-
formed only at baseline (10).
Quantification of change in IPH vol-
ume in asymptomatic individuals may 
contribute to identification of new risk 
factors for IPH development and pro-
gression and may yield further clues for 
effective cardiovascular prevention.
We used repeated MR imaging 
measurements to evaluate IPH develop-
ment and change in IPH volume over 
1.5 years of follow-up in asymptomatic 
subjects and to identify risk factors for 
IPH progression. We used a nested 
case-control design in 40 subjects with 
IPH at baseline and 27 subjects with-
out IPH at baseline from a community-
dwelling population of subjects older 
than 45 years.
Materials and Methods
Study Population
This study is embedded in the Rot-
terdam study (11), a prospective pop-
ulation-based cohort study limited to 
persons 45 years old or older. At study 
entry and every 3–4 years thereafter, 
all Rotterdam study participants are 
re-examined at a dedicated research 
center. From October 2007 on, ca-
rotid MR imaging was incorporated 
in the Rotterdam study in all persons 
with carotid intima-media thickening in 
one or both carotid arteries on sono-
grams (12). Between October 2007 
and November 2008, 360 participants 
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Advances in Knowledge
 n By using serial MR imaging in the 
detection and follow up of ca-
rotid intraplaque hemorrhage 
(IPH), we showed that qualita-
tively both progression (26%) 
and regression (30%) in IPH 
volume occurred frequently 
during follow-up, whereas quan-
titatively overall IPH volume 
decreased by a mean of 213.7 
mm3 6 62.6 per year.
 n We found smoking and hyperten-
sion to be the most important 
potentially modifiable risk factors 
for increase in IPH volume; in 
smokers versus nonsmokers, the 
mean increase in IPH over 1.4 
years was 45.2 mm3 (95% confi-
dence interval [CI]: 7.1, 83.4; P 
= .020), and in subjects with hy-
pertension versus those without 
hypertension, mean increase in 
IPH over 1.4 years was 32.5 mm3 
(95% CI: 7.7, 57.2; P = .010).
Implication for Patient Care
 n A better understanding of factors 
driving progression of vulnerable 
plaque components might ulti-
mately lead to early treatment 
and prevention of IPH.
Vulnerable atherosclerotic plaques are considered to lead to cardio-vascular events through plaque 
rupture and thromboembolism (1). 
Magnetic resonance (MR) imaging is a 
validated tool with which to assess im-
aging morphology and composition of 
the carotid atherosclerotic plaque. In-
traplaque hemorrhage (IPH) has been 
shown to be an important marker of 
plaque progression and destabilization 
through proinflammatory response, 
lipid accumulation, and accelerated 
progression in plaque burden (2–4).
It is important to understand the 
development and natural course of 
IPH to identify potentially modifiable 
factors; however, these processes re-
main poorly understood. In a previ-
ous hospital-based serial MR imaging 
study, IPH was related to an increase 
in necrotic core size and plaque bur-
den both in subjects with advanced 
carotid atherosclerotic disease (range, 
50%–79% stenosis) and in subjects 
with less than 50% stenosis. In previous 
studies, changes in IPH presence over 
time were shown in only those subjects 
with advanced carotid stenosis (5–7). A 
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presence of IPH, and IPH volume (in 
cubic millimeters) were measured on 
both sides in each carotid artery at 
baseline and at follow-up, and changes 
were evaluated per carotid artery and 
were compared between carotids with 
IPH and those without IPH at base-
line. Differences between subjects with 
IPH and control subjects or between 
baseline and follow-up were calculated 
with the Student t test or paired t test 
for continuous variables and with the 
x2 test or McNemar test for categori-
cal variables, respectively. Correlation 
between IPH volume change assessed 
with the automated segmentation tool 
and with the visual rating score was 
studied by using Kendall t b bivariate 
correlation.
We used linear regression models to 
analyze determinants of change in IPH 
volume restricted to all carotid arteries 
with IPH at baseline or at follow-up 
(17). IPH volume at follow-up (auto-
mated quantification) was chosen as an 
outcome in these analyses, and we ad-
justed for IPH volume at baseline (uni-
variate model). Additional adjustments 
were performed (multivariate model) 
for age, sex, carotid plaque thickness, 
time between examinations, and car-
diovascular risk factors (smoking, hy-
pertension, hypercholesterolemia, and 
diabetes mellitus). Additionally, we 
used ordinal logistic regression to an-
alyze determinants of change in visual 
rating score of IPH volume restricted to 
all carotid arteries with IPH at baseline 
or follow-up (Appendix E1 [online]).
To adjust for the correlation and po-
tential confounding bias between both 
carotid arteries within one participant, 
we followed a generalized estimation 
equation approach, with an indepen-
dent or unstructured working correla-
tion matrix that included two levels per 
participant, namely the left and right 
carotid artery. The generalized esti-
mation equation can handle correlated 
response data, particularly if responses 
are binary, preventing possible bias from 
paired arteries not being independent 
data points. Statistical software (SPSS, 
version 21.0; IBM, Armonk, NY) was 
used for all analyses. The P value thresh-
old for significance was .05.
algorithm developed in-house to measure 
IPH volume (in cubic millimeters) at 
baseline and at follow-up (Fig E1 [on-
line]) (14). In short, IPH segmentation 
was performed with a piecewise smooth 
regional level set method, which was 
initialized by three user-selected seed 
points. A region of interest was then au-
tomatically generated around the seed 
points. The accuracy, reproducibility, 
and robustness of this semiautomated 
method have been described previously, 
with a dice similarity coefficient of 0.88 
when compared with manual segmenta-
tion and an interscan robustness corre-
lation dice similarity coefficient of 0.99 
(14). For 20 examinations performed 
less than 1 week apart in a reproduc-
ibility assessment, pooled standard de-
viation for this quantitative IPH mea-
surement was 9.5 mm3 at a mean IPH 
volume of 143.5 mm3, with a coefficient 
of variation of 7.6%.
Cardiovascular Risk Factors
Covariates were ascertained at the 
time of baseline MR imaging or at the 
time of closest previous study cen-
ter visit and home interview by using 
standard procedures, as described 
previously (15). The body mass index 
was calculated based on weight and 
height. Blood pressure was measured 
at the study center visit. Serum total 
cholesterol and high-density lipopro-
tein cholesterol levels were measured. 
Smoking status was classified as cur-
rent, past, or never. Diabetes mellitus 
was considered present when the fast-
ing blood glucose level exceeded 7.0 
mmol/L, when the nonfasting glucose 
level exceeded 11.0 mmol/L, or when 
antidiabetic medication was used. Hy-
pertension was considered present if 
the subject used antihypertensive med-
ication or if his or her blood pressure 
was 140/90 mmHg or higher. History 
of myocardial infarction or stroke was 
assessed until the date of inclusion. All 
participants were observed for occur-
rence of major coronary or cerebro-
vascular events during follow-up (16).
Data Analysis
Maximum plaque thickness (in milli-
meters), degree of carotid stenosis, 
elsewhere (12) and included an inter-
mediate-weighted fast spin-echo black-
blood sequence and a three-dimension-
al T1-weighted gradient-echo sequence. 
Carotid wall thickness (in millimeters) 
and stenosis (in percentage) based 
on the North American Symptomatic 
Carotid Endarterectomy Trial (or NA-
SCET) criteria (13) were manually as-
sessed on MR images obtained with the 
intermediate-weighted fast spin-echo 
black-blood sequence. Evaluation of the 
presence of IPH was performed by one 
trained observer (Q.J.A.v.d.B., 4 years 
of experience) using the three-dimen-
sional T1-weighted gradient-echo MR 
imaging sequence; presence of IPH was 
defined as a hyperintense region in the 
atherosclerotic plaque. Previously as-
sessed interobserver reliability between 
this reader (Q.J.A.v.d.B.) and a second 
reader (A.v.d.L., 8 years of experience) 
was very good, with Cohen k values of 
0.85–0.95 (12).
Qualitative and Quantitative Assessment 
of Change in IPH
Qualitative assessment of IPH change 
from baseline to follow-up was per-
formed by two independent raters 
(Q.J.A.v.d.B. and M.S., 3 years of ex-
perience) in consensus using a visual 
rating scale in all 67 participants. Both 
raters were trained in detection of IPH 
and were working under the supervi-
sion of a neuroradiologist (A.v.d.L.). 
The observers were presented with the 
baseline and follow-up T1-weighted MR 
images in a random order and were 
blinded to information about when the 
images were obtained. First, the pres-
ence of IPH was scored, and subse-
quently a change in IPH size was scored 
on a five-point scale, ranging from 22 
(remarkable regression of more than 
50% or disappearance of IPH) to +2 
(remarkable progression of more than 
50% or newly developed IPH). If there 
was no apparent difference, it was 
scored as 0. Inter- and intraobserver 
reliability (Q.J.A.v.d.B.. M.S.) with the 
visual rating scale (n = 20) was good, 
with Cohen k values of 0.81 and 0.89, 
respectively.
For quantitative analysis of IPH vol-
ume change, we used a semiautomated 
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was an increase in IPH volume of more 
than 25 mm3 (mean increase, 70 mm3 
6 49). Conversely, in 16 (30%) carotid 
arteries with IPH, there was a decrease 
in IPH volume of more than 25 mm3 
(mean decrease, 82 mm3 6 67). Cor-
relation between automated IPH vol-
ume change and the visual rating scale 
was 0.41 (P , .001). Carotid arteries 
with persistent IPH at baseline and at 
follow-up, those with disappearance of 
IPH at follow-up, those with new IPH at 
follow-up, and those without IPH at ei-
ther time point showed a mean annual 
change in maximum plaque thickness of 
0.2 mm 6 0.6, 20.1 mm 6 0.1, 0.2 
mm 6 0.6, and 0.1 mm 6 0.4, respec-
tively (P . .05).
Table 3 shows cardiovascular risk 
factors associated with change in ca-
rotid IPH volume. Male sex was asso-
ciated with IPH volume progression 
(mean annual increase in IPH volume 
in male participants vs female partic-
ipants, 37.7 mm3; 95% confidence in-
terval [CI]: 11.1, 64.4; P = .006). This 
association was independent from age 
and other factors (multivariate model) 
(P = .002). Furthermore, hypertension 
(mean increase in IPH volume in partic-
ipants with hypertension vs those with-
out hypertension, 32.5 mm3; 95% CI: 
7.7, 57.2; P = .010) and smoking (mean 
increase in IPH volume in current 
smokers vs those who never smoked, 
45.2 mm3; 95% CI: 7.1, 83.4; P = .020) 
were associated with progression of 
IPH volume. These associations were 
borderline significant (P = .060 and P 
= .057, respectively) when adjusted 
for age and other factors (multivariate 
model). Associations were unaffected 
when we restricted the analysis in the 
subgroup of carotid plaques with IPH at 
baseline (n = 53), thereby eliminating 
the effect of increasing plaque thick-
ness and degree of stenosis in plaques 
with new IPH (Table E1 [online]). In the 
subgroup of five subjects with new IPH, 
three were male, all five had hyperten-
sion, and two were current smokers.
Conversely, albeit not significant, 
for carotid stenosis of more than 50%, 
there was the suggestion of a relation-
ship with regression of IPH volume 
(232.6 mm3; 95% CI: 284.5, 19.2; 
three (6%) and moderately in 11 (21%) 
of the 53 carotid arteries with IPH at 
baseline; there was no change in 23 
(43%) arteries, and IPH volume re-
gressed moderately in 12 (23%) and re-
markably in four (8%) arteries (Fig 2). 
Table E1 (online) shows cardiovascular 
risk factors associated with change in 
visual rating score of IPH volume. Hy-
pertension (P = .070, not significant) 
and current smoking (P = .020) were 
associated with an increase in the vi-
sual rating score.
Automated Rating
Automated volumetric segmentation 
in the five carotid arteries with newly 
developed IPH showed an IPH volume 
of 59.2 mm3 6 34.7 during 17 months 
of follow-up, corresponding to an an-
nual IPH volume growth of 44.7 mm3 
6 28.3. Automated quantification of all 
arteries with IPH at baseline showed a 
mean decrease in IPH volume of 219.8 
mm3 6 79.9 during follow-up, corre-
sponding to an annual change in IPH 
volume of 213.7 mm3 6 62.6. In 11 
(21%) carotid arteries with IPH, there 
Results
Table 1 shows characteristics of all 67 
subjects in the study population. Figure 
1 is a flowchart showing breakdown of 
all 124 carotid arteries included in the 
study. In the 40 participants with IPH at 
baseline MR imaging, bilateral carotid 
wall thickening was present in 34; in 
the remaining six, carotid wall thicken-
ing was unilateral (in total, there were 
74 carotid arteries with plaques). In 53 
(72%) of these carotid plaques, IPH was 
present at baseline. In the 27 matched 
control subjects without IPH, bilateral 
carotid wall thickening was present in 
23, unilateral wall thickening was pre-
sent in three, and carotid artery occlu-
sion was present in one (in total, there 
were 50 carotid arteries with plaque, all 
without IPH) (Fig 1).
Visual Rating
Table 2 shows carotid plaque character-
istics at baseline and at follow-up. New 
IPH developed in five (7%) of 71 ca-
rotid arteries without IPH at baseline. 
IPH volume progressed remarkably in 
Table 1
Subject Characteristics at Baseline
Characteristic
All Subjects  
(n = 67)
Case Subjects  
(n = 40)
Control Subjects  
(n = 27) P Value
Age (y)* 71.3 6 10.9 71.0 6 11.2 71.9 6 10.7 .39
Male sex 48 (72) 30 (75) 18 (67) .46
Hypertension 47 (70) 28 (70) 19 (70) .98
Diastolic blood pressure (mmHg)* 80 6 13 78 6 13 82 6 12 .04
Systolic blood pressure (mmHg)* 146 6 22 144 6 23 147 6 21 .90
Use of blood pressure–lowering drugs 36 (54) 25 (62) 11 (41) .08
Hypercholesterolemia 18 (27) 13 (32) 5 (19) .21
High-density lipoprotein level (mmol/L)* 1.3 6 0.4 1.2 6 0.3 1.5 6 0.4 .02
Use of cholesterol-lowering medication 29 (43) 17 (42) 12 (44) .88
Body mass index (kg/m2)* 27.4 6 3.8 27.6 6 3.9 27.1 6 3.8 .86
Diabetes mellitus 16 (24) 12 (30) 4 (15) .15
Current or past smoking 53 (79) 35 (88) 18 (67) .04
Previous cardiovascular disease 10 (15) 5 (12. 5 (19) .50
Previous stroke 4 (6) 4 (10) 0 (0) .09
Maximum plaque thickness (mm)* 4.2 6 1.2 3.9 6 0.8 4.5 6 1.3 .01
Interval between two MR imaging  
examinations (y)*
1.3 6 0.3 1.3 6 0.3 1.4 6 0.3 .03
Note.—Unless otherwise indicated, data are number of subjects, and data in parentheses are percentages. P values for 
difference between subjects with IPH and control subjects were calculated with the Student t test for continuous variables and 
with the x2 test for categorical variables.
* Data are mean 6 standard deviation.
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Figure 1
Figure 1: Study population flowchart shows number of carotid arteries with and without IPH at baseline. A carotid plaque 
was considered a carotid wall thickness of more than 2 mm on intermediate-weighted fast spin-echo black-blood MR images.
Table 2
Baseline and Follow-up Measurements of Plaque Characteristics in 124 Carotid Plaques
Characteristic
Carotids with IPH at Baseline (n = 53) Carotids without IPH at Baseline (n = 71)
Baseline Follow-up P Value Baseline Follow-up P Value
Visual presence of IPH 53 (100) 50 (94) .72 0 (0) 5 (7) .56
Visual change at follow-up
 Remarkable progression … 3 (6) … … 5 (7) …
 Moderate progression … 11 (21) … … … …
 No change … 23 (43) … … … …
 Moderate regression … 12 (23) … … … …
 Remarkable regression … 4 (8) … … … …
Volume (mm3)* 109.3 6 120.0 89.9 6 103.6 .08 … 59.2 6 34.7 …
Maximum plaque thickness (mm)* 4.1 6 1.1 4.3 6 1.1 .07 3.4 6 0.9 3.6 6 0.8 .06
Degree of stenosis (%)* 23.4 6 19.0 24.9 6 19.8 .35 10.7 6 13.9 13.3 6 15.6 .04
Note.—Unless otherwise indicated, data are number of subjects, and data in parentheses are percentages. P values for difference between baseline and follow-up values were evaluated with a paired 
t test for continuous variables and with a McNemar test for categorical variables.
* Data are mean 6 standard deviation.
P = .217), and this association became 
stronger when additionally adjusted 
for carotid wall thickness (236.5 mm3; 
95% CI: 277.5, 4.4; P = .081).
Overall, 43% of the subjects 
used cholesterol-lowering medica-
tion. This percentage was compa-
rable in all groups with visual IPH 
change. Use of cholesterol-lowering 
medication also was not associated 
with change in absolute IPH volume 
(P = .31).
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There were no cardiovascular or 
cerebrovascular events during follow-up 
in any of the 67 subjects.
Discussion
In this case-control MR imaging study 
in community-dwelling subjects with 
carotid atherosclerosis, we showed that 
qualitatively, both progression and re-
gression in IPH volume occur frequently 
over time, whereas quantitatively over-
all IPH volume decreases, albeit with 
wide variation. Male sex, smoking, and 
hypertension were all associated with 
an increase in IPH volume over time. 
Conversely, moderate to severe carotid 
stenosis seemed to be associated with a 
decrease in IPH volume.
In contrast to findings in previous 
studies (5–7), subjects in our study 
were not symptomatic but were ran-
domly selected from a large sample of 
subjects with preclinical atherosclero-
sis. Thus, our results are more repre-
sentative of the natural course of IPH 
and are of interest in view of potential 
preventive measures.
MR imaging signal for IPH re-
mained detectable in the majority of 
carotid plaques after 17 months. Our 
findings are in agreement with those of 
Yamada et al (18), who reported that in 
one of 30 carotid arteries, MR imaging 
signal intensity for IPH changed during 
a median interval of approximately 9 
months. Also, Takaya et al (6) reported 
that IPH remained detectable in the 
same plaque after 18 months. It was 
suggested that either (a) IPH does not 
resolve by an atypical degradation of he-
moglobin or (b) IPH recurs in the same 
plaque repetitively (19). In our present 
study, we expounded on these findings 
by showing that despite persistence of 
high signal intensity within the plaques, 
both visual rating and automated as-
sessment indicate that IPH may regress 
over a short follow-up period.
It is important to assess poten-
tial modifiable risk factors for devel-
opment or growth of IPH, as IPH is 
considered a major risk indicator for 
plaque instability and subsequent ce-
rebrovascular events (2–4,20). In a 
previous study in 1006 asymptomatic 
Figure 2
Figure 2: Examples of remarkable regression and progression of IPH volume during 
follow-up. T1-weighted gradient-echo MR images of carotid atherosclerotic plaques with 
IPH in three subjects at baseline and follow-up. A, Images in a 63-year-old man at baseline 
and at 1-year follow-up. With the visual rating scale, there is a remarkable decrease in IPH 
volume. IPH volume regression was 2255 mm3, as measured with the semiautomated tool. 
B, Images in a 60-year-old man at baseline and at 1-year follow-up. With the visual rating 
scale, there is a moderate increase in IPH volume. IPH volume progression was 62 mm3, as 
measured with the semiautomated tool. C, Images in a 56-year-old man at baseline and at 
1.5-year follow-up. With the visual rating scale, there is a remarkable increase in IPH volume. 
IPH volume progression was 173 mm3, as measured with the semiautomated tool. Note the 
lumen of the internal carotid artery (∗) and the IPH (arrows) (the area of high signal intensity) 
on all images.
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visual assessment and automated as-
sessment. Our automated tool was not 
designed to measure vulnerable plaque 
components other than IPH (eg, fibrous 
cap thickness, lipid core size), thereby 
leaving out other important factors of 
plaque instability. Finally, we studied 
cardiovascular risk factors in a dichot-
omous distribution. Although this facil-
itates clinical interpretation and com-
parison to other studies, it may have 
led to a lower sensitivity in the detec-
tion of associations.
Recently, different stages of IPH 
have been characterized (recent, or-
ganized, amorphous). These different 
stages may represent the morphologic 
substrates of different types of repair 
response to the plaque hemorrhage 
(25). It has been reported that IPH can 
induce a healing response at the site 
of the hemorrhage with the formation 
of fibrous and calcified tissue, which 
ultimately leads to plaque stabilization 
(26). This could explain the decrease 
in mean IPH volumes with a concur-
rent increase in atherosclerotic plaque 
burden in our study. Unfortunately, we 
were not able to distinguish these dif-
ferent stages of IPH with our MR im-
aging protocol. The only determinant 
we found in our study to potentially 
relate to IPH regression was carotid 
stenosis of more than 50%. This may 
be explained by altered hemodynamic 
factors and wall shear stress in subjects 
with high-grade stenosis, reducing the 
strain on the plaque. Future studies 
should focus on the exact mechanism, 
as well as on finding other potentially 
modifiable determinants for regression 
of IPH burden, as this may affect in-
terventional strategies to reduce plaque 
vulnerability.
In conclusion, serial MR imaging 
of carotid arteries in community-dwell-
ing subjects with subclinical carotid 
atherosclerosis over a 17-month pe-
riod showed new IPH development in 
plaques that were previously negative 
for IPH. In plaques containing IPH at 
baseline, both visual and quantitative 
progression and regression in IPH vol-
ume occurred, suggesting that IPH is 
a dynamic process with both growth 
and resolution over time. We found 
was not quantified. Two previous serial 
MR imaging studies in a hospital set-
ting showed an increase in total plaque 
burden in the presence of IPH (5–7), 
suggesting that IPH may drive plaque 
growth. We used plaque thickness as 
a proxy for plaque burden and found 
an equal increase in plaque thickness 
over time between arteries with IPH 
and those without, though plaques with 
IPH were thicker, on average. Both of 
these previous studies considered IPH 
only as a dichotomous variable. Thus, 
our study adds more understanding on 
IPH change over time.
Limitations of our study must be 
discussed. We have not taken the lo-
cation of the IPH within the carotid 
plaque into account. Thus, we cannot 
be sure whether the IPHs observed at 
follow-up were at the same location as 
those observed at baseline or if some 
of these may also represent newly de-
veloped IPH. In our visual assessment, 
however, we found that in 94% of the 
subjects, IPH remained present, which 
is in agreement with findings in two 
previous studies (6,24). Still, we may 
have underestimated the rate of new 
IPH development, as this would have 
been scored as growth of IPH with both 
community-dwelling subjects with ath-
erosclerotic carotid plaques, male sex, 
hypertension, and current smoking 
were major risk factors for presence 
of IPH (12). In the current study, we 
extended these findings to IPH volu-
metric change. We showed male sex, 
hypertension, and smoking were inde-
pendently associated with IPH growth. 
Nicotine has been found to play an im-
portant stimulating role in angiogenesis 
and plaque growth, which may explain 
the growth in IPH volume that we found 
in smokers (21,22). In vitro studies that 
subject the vessel wall in specific vascu-
lar smooth muscle cells to cyclic strain 
showed upregulation of vascular endo-
thelial growth factor, which is an indi-
cator of angiogenesis (23). This may 
explain our findings in subjects with 
hypertension. However, further investi-
gations are necessary to elucidate the 
exact pathophysiologic mechanism of 
IPH development and growth.
In a study in 73 subjects with asymp-
tomatic carotid stenosis of 50%–70%, a 
scoring system using plaque character-
istics (wall thickness and lipid core) was 
associated with presence of IPH (8), al-
beit not with newly developed IPH (9). 
In both articles, IPH volume or growth 
Table 3
Cardiovascular Risk Factors and Carotid IPH Volume Change at Follow-up
Characteristic Model 1 (mm3) P Value Model 2 (mm3) P Value
Follow-up time 22.4 (251.3; 46.5) .924 26.2 (267.2; 54.8) .843
Male sex 37.7 (11.1; 64.4) .006 40.5 (14.5; 66.5) .002
Age 20.4 (22.1; 1.3) .644 0.5 (21.1; 2.2) .512
Maximum plaque thickness 5.0 (210.5; 20.5) .527 7.4 (29.3; 24.0) .385
Degree of carotid stenosis 0.0 (21.0; 1.0) .972 0.1 (21.1; 1.4) .837
Carotid stenosis of 50% 232.6 (284.5; 19.2) .217 226.8 (278.4; 24.8) .308
Smoking
 Past vs never 34.3 (10.0; 58.5) .006 12.0 (212.6–36.6) .340
 Current vs never 45.2 (7.1; 83.4) .020 35.0 (21.0; 71.1) .057
Body mass index 21.4 (25.4; 2.5) .486 21.3 (25.2; 2.7) .539
Hypertension 32.5 (7.7; 57.2) .010 24.4 (21.0; 49.8) .060
Diabetes mellitus 24.3 (240.6; 31.9) .815 25.0 (243.5; 33.6) .798
Hypercholesterolemia 218.6 (255.3; 18.1) .320 214.7 (260.1; 30.7) .525
High-density lipoprotein level 233.6 (293.5; 26.2) .271 224.9 (283.9; 34.1) .408
Use of cholesterol-lowering 
medication
20.1 (218.4; 58.8) .306 26.2 (212.5; 64.9) .184
Note.—Data are difference in IPH volume per unit increase of the cardiovascular risk factors at baseline. Data in parentheses 
are the 95% CI. Model 1= univariate analysis. Model 2 = multivariate analysis adjusted for baseline IPH volume, age, sex, and 
all other covariates in the univariate analysis with P  .10 (smoking and hypertension), when applicable.
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smoking and hypertension to be the 
most important potentially modifiable 
risk factors for increase in IPH volume. 
Further studies are needed to corrob-
orate our findings and to increase our 
understanding of the mechanisms lead-
ing to progression of atherosclerotic 
plaques and cerebrovascular events.
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